We conducted a study of patients with acute pulmonary embolism and pulmonary hypertension or right ventricular dysfunction but without arterial hypotension or shock. The patients were randomly ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Stroke patients ...

In a meta-analysis presented at the European Stroke Organization Conference, alteplase was more effective than placebo for treatment of acute ischemic stroke between 4.5 and 9 hours after onset.

Alteplase (Actilyse, Boehringer Ingelheim) is a tissue plasminogen activator manufactured by recombinant DNA technology. It activates the production of plasmin from its precursor plasminogen. Plasmin ...

Please provide your email address to receive an email when new articles are posted on . In a phase 2 study, reteplase demonstrated similar efficacy and safety vs. alteplase for the treatment of acute ...

The bolus thrombolytic, tenecteplase, was non-inferior to alteplase, which is given by a bolus followed by an infusion, for functional outcomes in acute ischemic stroke patients treated within 4½ ...

The UK medicines watchdog is to review the safety of a clot-busting drug often used to treat strokes. The Medicines and Healthcare products Regulatory Agency believes the benefits of alteplase ...

The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary ...

"This was a pivotal trial in establishing the safety and efficacy of tenecteplase as an alternative to alteplase in the thrombolytic treatment of acute ischemic stroke within 4.5 hours in Asian ...

Recent use of direct oral anticoagulants (DOACs) does not seem to be associated with increased risk of intracranial hemorrhage among patients with acute ischemic stroke treated with intravenous ...